Home › Compare › CVVIF vs ABBV
CVVIF yields 31.45% · ABBV yields 3.06%● Live data
📍 CVVIF pulled ahead of the other in Year 1
Combined, CVVIF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CVVIF + ABBV for your $10,000?
Sociedad Comercial del Plata S.A. operates in construction, energy, transportation, and real estate sectors in Argentina and internationally. The company operates through Construction, Oil, Agribusiness, and Entertainment segments. It provides construction materials, such as bricks, tiles, floors and coatings, ceramics, porcelain tiles, and glasses for the construction industry. The company also engages in the development, exploration, and production of hydrocarbons, as well as trunk transportation of gas. In addition, the company offers omega grains; offers rail freight services for transporting grains from the humid pampas to the port; and invests in own securities, real estate development projects, and forestry. Further, it processes crude oil; markets fuels, lubricants, greases, and asphalt; and offers fuel storage and dock services. Additionally, the company manufactures frozen pre-fried potatoes; and operates amusement parks, theatres, and water parks. Sociedad Comercial del Plata S.A. was incorporated in 1927 and is based in Buenos Aires, Argentina.
Full CVVIF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.